# Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event

> **NCT02661217** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1002 (actual)

## Conditions studied

- Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** LCZ696

## Key facts

- **NCT ID:** NCT02661217
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-12
- **Primary completion:** 2018-02-20
- **Final completion:** 2018-06-20
- **Target enrollment:** 1002 (ACTUAL)
- **Last updated:** 2021-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02661217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02661217, "Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02661217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*